


Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-16 (canceled)

17. (previously presented) A pharmaceutical formulation comprising an aqueous solution of a dissolved physiologically acceptable salt and a pharmaceutically acceptable salt of a compound represented in the general formula (II):



Formula II

wherein, as valence and stability permit,

$R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$ , independently for each occurrence, represent H, lower alkyl,  $-(CH_2)_n$ aryl, or  $-(CH_2)_n$ heteroaryl;

$L$ , independently for each occurrence, is absent or represents  $-(CH_2)_n$ -,  $-alkenyl$ -,  $-alkynyl$ -,  $-(CH_2)_nalkenyl$ -,  $-(CH_2)_nalkynyl$ -,  $-(CH_2)_nO(CH_2)_p$ -,  $-(CH_2)_nNR_8(CH_2)_p$ -,  $-(CH_2)_nS(CH_2)_p$ -,  $-(CH_2)_nalkenyl(CH_2)_p$ -,  $-(CH_2)_nalkynyl(CH_2)_p$ -,  $-O(CH_2)_n$ -,  $-NR_8(CH_2)_n$ -, or  $-S(CH_2)_n$ ;

$X$  is selected, independently, from  $-N(R_8)$ -,  $-O$ -,  $-S$ -,  $-(R_8)N-N(R_8)$ -,  $-ON(R_8)$ -, and a direct bond;

$Y$  and  $Z$ , independently, are selected from O and S;

R<sub>8</sub>, independently for each occurrence, represents H, lower alkyl, -(CH<sub>2</sub>)<sub>n</sub>aryl, or -

(CH<sub>2</sub>)<sub>n</sub>heteroaryl, or two R<sub>8</sub> taken together may form a 4- to 8-membered ring;

M is absent or represents L, -SO<sub>2</sub>L-, or -(C=O)L-;

p represents, independently for each occurrence, an integer from 0 to 3;

n, individually for each occurrence, represents an integer from 0 to 5; and


q, r, and s represent, independently for each occurrence, an integer from 0 to 2.

18. (original) The formulation of claim 17, wherein Y and Z each represent O.
19. (original) The formulation of claim 17, wherein the sum of q, r, and s is less than 4.
20. (original) The formulation of claim 17, wherein at least one of R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> includes an aryl group.
21. (original) The formulation of claim 17, wherein XLR<sub>4</sub> includes a cyclic diamine.
22. (original) The formulation of claim 17, wherein X is included in a diazacyclobutane.
23. (original) The formulation of claim 17, wherein R<sub>1</sub> represents a branched alkyl, a cycloalkyl, or a cycloalkylalkyl.
24. (original) The formulation of claim 17, wherein L attached to R<sub>1</sub> represents O, S, or NR<sub>8</sub>.
25. (original) The formulation of claim 17, wherein the salt is a chloride, bromide, iodide, succinate, tartrate, lactate, mesylate, or maleate salt.
26. (canceled)
27. (previously presented) The formulation of claim 17, wherein the salt is sodium acetate.
28. (original) The formulation of claim 17, wherein the aqueous solution further includes a solute selected from dextrose, lactose, mannitol, or another polyhydroxylated compound.

29. (original) The formulation of claim 17, wherein the aqueous solution has an osmolarity between 200 and 400 mOsm.
30. (original) The formulation of claim 17, wherein the solution has a pH in the range of 3 to 6.
31. (original) The formulation of claim 17, wherein the formulation is suitable for topical administration.

Claims 32-46 (canceled)

47. (previously presented) A pharmaceutical formulation comprising an aqueous solution of a dissolved physiologically acceptable salt and a pharmaceutically acceptable salt of a compound represented in the general formula (IV):



Formula IV

wherein, as valence and stability permit,

$R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$ , independently for each occurrence, represent H, lower alkyl,  $-(CH_2)_n$ aryl, or  $-(CH_2)_n$ heteroaryl;

$L$ , independently for each occurrence, is absent or represents  $-(CH_2)_n$ -,  $-alkenyl$ -,  $-alkynyl$ -,  $-(CH_2)_nalkenyl$ -,  $-(CH_2)_nalkynyl$ -,  $-(CH_2)_nO(CH_2)_p$ -,  $-(CH_2)_nNR_8(CH_2)_p$ -,  $-(CH_2)_nS(CH_2)_p$ -,  $-(CH_2)_nalkenyl(CH_2)_p$ -,  $-(CH_2)_nalkynyl(CH_2)_p$ -,  $-O(CH_2)_n$ -,  $-NR_8(CH_2)_n$ -, or  $-S(CH_2)_n$ ;

$X$  is selected, independently, from  $-N(R_8)$ -,  $-O$ -,  $-S$ -,  $-(R_8)N-N(R_8)$ -,  $-ON(R_8)$ -, and a direct bond;

$R_8$ , independently for each occurrence, represents H, lower alkyl,  $-(CH_2)_n$ aryl, or  $-(CH_2)_n$ heteroaryl, or two  $R_8$  taken together may form a 4- to 8-membered ring;

M is absent or represents L,  $-\text{SO}_2\text{L}-$ , or  $-(\text{C}=\text{O})\text{L}-$ ;

p represents, independently for each occurrence, an integer from 0 to 3; and

n, individually for each occurrence, represents an integer from 0 to 5.

48. (original) The formulation of claim 47, wherein  $\text{R}_1$  represents a branched alkyl, a cycloalkyl, or a cycloalkylalkyl.

49. (original) The formulation of claim 47, wherein at least one of  $\text{R}_1$ ,  $\text{R}_2$ , and  $\text{R}_3$  includes an aryl group.

50. (original) The formulation of claim 47, wherein  $\text{XLR}_4$  includes a cyclic amine.

51. (original) The formulation of claim 47, wherein X is part of a diazacyclobutane.

52. (original) The formulation of claim 47, wherein the salt is a chloride, bromide, iodide, succinate, tartrate, lactate, mesylate, or maleate salt.

53. (canceled)

54. (previously presented) The formulation of claim 47, wherein the salt is sodium acetate.

55. (original) The formulation of claim 47, wherein the aqueous solution further includes a solute selected from dextrose, lactose, mannitol, or another polyhydroxylated compound.

56. (original) The formulation of claim 47, wherein the aqueous solution has an osmolarity between 200 and 400 mOsm.

57. (original) The formulation of claim 47, wherein the solution has a pH in the range of 3 to 6.

58. (original) The formulation of claim 47, wherein the formulation is suitable for topical administration.

Claims 59-93 (canceled)